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Abstract
Background: Age at menarche has been associated with various health outcomes. We aimed to identify potential
causal effects of age at menarche on health-related traits in a hypothesis-free manner.
Methods: We conducted a Mendelian randomization phenome-wide association study (MR-pheWAS) of age at
menarche with 17,893 health-related traits in UK Biobank (n = 181,318) using PHESANT. The exposure of interest was
the genetic risk score for age at menarche. We conducted a second MR-pheWAS after excluding SNPs associated
with BMI from the genetic risk score, to examine whether results might be due to the genetic overlap between age
at menarche and BMI. We followed up a subset of health-related traits to investigate MR assumptions and seek
replication in independent study populations.
Results: Of the 17,893 tests performed in our MR-pheWAS, we identified 619 associations with the genetic risk
score for age at menarche at a 5% false discovery rate threshold, of which 295 were below a Bonferroni-corrected
P value threshold. These included potential effects of younger age at menarche on lower lung function, higher heel
bone-mineral density, greater burden of psychosocial/mental health problems, younger age at first birth, higher risk
of childhood sexual abuse, poorer cardiometabolic health, and lower physical activity. After exclusion of variants
associated with BMI, the genetic risk score for age at menarche was related to 37 traits at a 5% false discovery rate,
of which 29 were below a Bonferroni-corrected P value threshold. We attempted to replicate findings for bone-
mineral density, lung function, neuroticism, and childhood sexual abuse using 5 independent cohorts/consortia.
While estimates for lung function, higher bone-mineral density, neuroticism, and childhood sexual abuse in
replication cohorts were consistent with UK Biobank estimates, confidence intervals were wide and often included
the null.
Conclusions: The genetic risk score for age at menarche was related to a broad range of health-related traits.
Follow-up analyses indicated imprecise evidence of an effect of younger age at menarche on greater bone-mineral
density, lower lung function, higher neuroticism score, and greater risk of childhood sexual abuse in the smaller
replication samples available; hence, these findings need further exploration when larger independent samples
become available.
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Background
Menarche (onset of menses) is a hallmark event in a
woman’s life. Using conventional multivariable regression,
a younger age at menarche has been associated with
higher risk of death from all causes [1], death from cardio-
vascular disease [1, 2], reproductive cancers [3, 4], and de-
pression [5], but lower risk of osteoporosis/fractures [6, 7].
It has been proposed that the well-known inverse associ-
ation between childhood body mass index (BMI) and age
at menarche explains some of the observed associations
[8, 9]. However, due to the strong tracking of BMI across
the life-course, it is challenging to disentangle the role of
BMI as a potential confounder, as opposed to a mediator
of associations between age at menarche and health out-
comes [9]. It therefore remains unclear whether the previ-
ously reported associations between age at menarche and
health outcomes reflect a causal effect.
One way of evaluating causality is to use single nucleo-
tide polymorphisms (SNPs) as instrumental variables for
the exposure of interest (here age at menarche), under
the assumption that the allocation of SNPs at conception
is random and unrelated to potential confounding fac-
tors [10]. Mendelian randomization has previously been
used to explore effects of age at menarche on cardiomet-
abolic traits [9, 11, 12], depression [13, 14], breast cancer
[15, 16], educational level [17], lung function [18], osteo-
porosis [19], fracture risk [20], and reproductive/behav-
ioral outcomes [21]. However, these have focused on
hypothesized effects by exploring whether associations
that have been widely examined in the literature have
causal evidence from Mendelian randomization analyses.
This approach can miss novel potentially important
(unknown and unthought of effects). A hypothesis-free
approach specifically aims to go beyond that narrow
focus to gain new knowledge. For example, hypothesis-
free genome-wide association studies, in comparison to
candidate/hypothesized genetic association studies, have
efficiently identified novel biological understanding. It is
possible that a similar approach to a large group of non-
genetic outcomes could yield novel causal understand-
ing. Previous phenome-wide Mendelian randomization
studies of BMI and smoking have provided novel evi-
dence of effects on outcomes not previously identified
as being associated with these exposures [22, 23]. Fur-
thermore, as with previous candidate gene-association
studies, previous Mendelian randomization studies of
hypothesized associations had small sample sizes. The
large sample size used here supports more precise
estimates than these previous studies as well as the
potential for novel etiological understanding.
The objective of this study was to systematically
investigate causal effects of age at menarche on health-
related traits, by conducting a Mendelian randomization
phenome-wide association study (MR-pheWAS).
Methods
UK Biobank
The MR-pheWAS was undertaken in the UK Biobank
cohort. The UK Biobank cohort includes 503,325 people
(273,453 women) between 40 and 69 years of age, who
were recruited between 2006 and 2010, from 22 assess-
ment centers across England, Scotland, and Wales [24,
25]. The response rate was 5%, and all participants gave
written informed consent. Participants were followed
prospectively after enrolment using Hospital Episode
Statistics data, as well as data from cancer registries and
the Office of National Statistics. Age at menarche in
whole years was self-reported at the time of enrolment
(mean 44 years after the event). Genotyping was per-
formed using the Affymetrix UK BiLEVE Axiom array
on an initial 50,000 participants; the remaining 450,000
participants were genotyped using the Affymetrix UK
Biobank Axiom® array [26]. Quality control and imput-
ation (to over 90 million SNPs, indels, and large struc-
tural variants) was performed by the Wellcome Trust
Centre for Human Genetics [26, 27]. The data collection
in UK Biobank was approved by the NHS National
Research Ethics Service (ref 11/NW/0382). The current
analysis included 181,318 unrelated genotyped women
of European ancestry (Fig. 1). Relatedness was defined as
third degree relatives or closer [27].
Identifying genetic instruments for age at menarche
We used the findings from the most recent genome-
wide association study (GWAS) of age at menarche to
identify genetic instruments for our analysis [16]. This
study included 40 studies from the ReproGen consor-
tium (N = 179,117 women), in addition to 23andMe
(N = 76,831 women) and UK Biobank (N = 73,397
women). They identified 37,925 variants associated
with age at menarche (P value < 5 × 10−8) that repli-
cated across independent datasets, which constituted
389 independent signals. We generated an externally
weighted genetic risk score (GRS-all) as a weighted
sum of the number of age at menarche decreasing al-
leles across 360 SNPs, weighted by the published
GWAS effect estimates. The weights that we used in-
cluded a subpopulation of women participating in UK
Biobank included in our MR-PheWAS. Specifically,
up to 73,397 (40%) of the 181,318 women included in
our analyses contributed to the age at menarche
GWAS effect estimates. Thus, a higher GRS-all reflects
a younger age at menarche.
We hypothesized a priori that there could be horizon-
tal pleiotropic effects via childhood BMI, and that there
could plausibly be horizontal or vertical pleiotropic ef-
fects via adult BMI, which is itself influenced by child-
hood BMI (Fig. 2). Horizontal pleiotropy could bias our
findings. By contrast, vertical pleiotropy is part of the
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potential causal path between age at menarche and
health outcomes that we are aiming to estimate. We
used Steiger filtering to identify SNPs that explained
more of the variation in adult BMI than the variation
in age at menarche [28]. These SNPs are more likely
to bias findings due to horizontal pleiotropy via BMI
than SNPs that explain more of the variation of age
at menarche. We generated a GRS (GRSSteiger) exclud-
ing the SNPs (27 SNPs) that explained more of the
variation (quantified by the R2) in adult BMI than age
at menarche. We only had a measure of adult BMI
available in UK Biobank. Furthermore, 2 recent
GWAS studies identified 15 and 941 SNPs associated
with childhood and adult BMI, respectively [29, 30].
Of the 360 age at menarche SNPs included in our
GRS-all, 7 and 199 SNPs were identified in, or situ-
ated near to (defined as being within 500,000 bp),
SNPs identified in these childhood and adult BMI
GWAS, respectively. We therefore also generated 2
alternative age at menarche GRS, excluding the 7
childhood BMI (GRS-child BMI) and all 206 BMI
(GRS-BMI) associated SNPs, respectively.
Phenome-wide Mendelian randomization analysis
We conducted a MR-pheWAS using the publicly avail-
able PHEnome Scan ANalysis Tool (PHESANT) version
0.17 which uses an automated rule-based method [31].
The decision rules start with identifying continuous,
ordered categorical, unordered categorical, or binary
variable fields. After outcome pre-processing (continu-
ous traits were inverse normal rank transformed to en-
sure they were normally distributed), PHESANT runs
linear (continuous outcomes), logistic (binary outcomes),
ordered logistic (ordered categorical outcomes), and
multinomial logistic (unordered categorical outcomes)
regression, with the weighted allele score for age at me-
narche as the exposure. For unordered categorical out-
comes analyzed using multinomial logistic regression, no
beta coefficient or standard error is reported, but only
the overall P value for the association based on a likeli-
hood ratio test. All analyses are adjusted for age and the
first 10 genetic principal components. The latter are
used to account for population structure, which could
produce confounded estimates.
We used PHESANT to examine the association of the
age at menarche GRS with 17,893 health-related traits. To
identify potential causal effects of age at menarche, we
used 2 approaches that account for the number of tests
performed, to help us evaluate the strength of the evi-
dence from our MR-pheWAS. First, we derived a P value
threshold setting the false discovery rate at 5%. After rank-
ing the results by P value, this threshold is calculated as Pt
(rank) = 0.05 × rank/n, where n is the total number of tests
in the phenome scan and rank is the largest rank position
with a P value less than Pt. Second, we calculated a
Bonferroni-corrected P value threshold, by dividing 0.05
by the number of tests performed. The Bonferroni-
corrected P values assume that the tests conducted are in-
dependent. It is therefore likely to be an overly conserva-
tive correction for multiple testing, as several of the
health-related traits evaluated are known to be associated.
We reran our MR-pheWAS using our three alternative
GRS-Steiger, GRS-child BMI, and GRS-BMI scores as instru-
ments. We used quantile-quantile (QQ) plots to illustrate
how the distribution of the P values followed the distribu-
tion expected under the null hypothesis.
Follow-up and replication analyses
We conducted follow-up and replication analyses of
bone-mineral density (BMD), lung function, neuroticism,
and childhood sexual abuse. The estimated relationships
between the GRS-all and these outcomes were all below
the Bonferroni-corrected P value threshold in our main
MR-pheWAS including all SNPs in the genetic risk
score. They were further selected because of the novelty
(not previously studied in detail using Mendelian
randomization) and pragmatically—due to the
Fig. 1 Illustration of the study population
Magnus et al. BMC Medicine           (2020) 18:71 Page 3 of 17
availability of data to explore replication and potential
assumption violations. Furthermore, we specifically
chose not to follow-up any of the observed relationships
with cardiometabolic health outcomes due to the close
relationship with BMI.
We used information from 5 different cohorts/consor-
tia to replicate our findings. These included 2 published
GWAS studies of femoral neck (n = 22,990), lumbar
spine (n = 22,177), and heel (n = 4566) BMD from the
Genetic Factors for Osteoporosis (GEFOS) consortium
[32, 33]; 2 GWAS studies of lung function (1 from the
Cohorts for Heart and Aging Research in Genetic
Epidemiology (CHARGE) consortium (n = 60,552) [34]
and 1 from the SpiroMeta consortium (n = 79,055) [35]);
and 1 GWAS study of neuroticism from the Genetics of
Personality (GPC) consortium (n = 63,661) [36]. Replica-
tion analysis of childhood sexual abuse was done in the
Avon Longitudinal Study of Parents and Children
(ALSPAC, n = 5953) [37]. Detailed information of the
replication cohorts and the definition of the outcomes
used in the one- and two-sample Mendelian
randomization analysis in both UK Biobank and the rep-
lications cohorts is provided in Additional file 1.
The first step in our follow-up of the findings in the
MR-pheWAS was to estimate the magnitude of the
causal effects. While estimates from PHESANT measure
the association of the GRS with the outcomes (estimates
reflect the mean difference or log-odds in outcomes per
unit increase in the GRS), one- and two-sample Mendel-
ian randomization analyses are required to estimate the
Fig. 2 Directed acyclic graph. MR, Mendelian randomization; BMI, body mass index; MV, multivariable. We use hypothesis-free MR to explore the
potential effect of age at menarche (X) on outcomes (Y), by using SNPs that robustly relate to age at menarche as instrumental variables (Z). The
directed acyclic graph shows our key assumptions for the different genetic risk scores we use in our analyses. The black lines show this main
analysis; the heavily weighted black line indicated the effects we are interested in. The MR assumption that Z does not relate to Y other than
through X may be violated because of the known associations between some of the age at menarche SNPs and BMI. The genetic instrument Z
could be associated with the outcome due to horizontal pleiotropy via child BMI, either via its relation to adult BMI or directly (blue dashed
arrows). These paths could bias our MR results. Z could also be related to BMI via vertical pleiotropy through a path from Z to X, from X to adult
BMI, and from it to Y (green dashed-dotted arrows). This path implies adult BMI is part of the causal path from age at menarche to Y and would
not bias our results. We used four approaches to exploring these possibilities (table). We have not systematically explored other horizontally
pleiotropic pathways that could bias our results (red dotted line)
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magnitude of the causal effect of the exposure (per year
decrease in age at menarche). We estimated the magni-
tude of potential causal effects of age at menarche on
BMD, lung function, and neuroticism in both UK
Biobank and the replication cohorts using one- and
two-sample Mendelian randomization. We estimated
the effect of each age at menarche SNP on these out-
comes, then generated Wald ratios (the effect esti-
mate of each SNP on the outcome divided by the
effect estimate of each SNP on age at menarche), and
subsequently pooled these SNP-specific estimates
using random-effects inverse-variance weighting
(equivalent to random-effects meta-analysis). We used
one-sample Mendelian randomization analysis to esti-
mate the magnitude of the causal effect of age at me-
narche on childhood sexual abuse in both UK
Biobank and ALSPAC. This approach entailed first es-
timating the genetically predicted age at menarche
from a linear regression model including the weighted
GRS as a predictor (independent variable). We then
used this genetically predicted age at menarche as the
exposure in a logistic regression model of childhood
sexual abuse. We estimated the standard errors of the
second step using bootstrapping. The potential causal
effects were estimated using the GRS-all, GRS-Steiger,
and GRS-BMI as instruments.
Secondly, we conducted a number of sensitivity ana-
lyses in the two-sample Mendelian randomization
analysis to evaluate the assumption of no unbalanced
horizontal pleiotropic effects that underlies the approach
(Fig. 2). We estimated the effect using Mendelian
randomization-Egger (MR-Egger) regression. The esti-
mate of the causal effect from the MR-Egger regression
is unbiased if the strength of the gene-exposure associ-
ation does not correlate with the strength of the bias
due to horizontal pleiotropy (known as the Instrument
Strength Independent of Direct Effect, or InSIDE
assumption) [38]. A non-zero intercept from this regres-
sion model is an indicator of unbalanced horizontal
pleiotropy [38]. Additional sensitivity analyses included
simple and weighted mode-based and weighted median
regression [39]. We also used the Mendelian
randomization pleiotropy residual sum and outlier (MR-
PRESSO) test to identify possible bias from horizontal
pleiotropy [40]. This includes a global test which evalu-
ates the overall evidence of horizontal pleiotropy, an
outlier-corrected causal estimate which corrects for the
detected horizontal pleiotropy, and a distortion test
which estimates if the causal effect estimate is different
before and after adjustment for outliers (with a P value
of < 0.05). We present the outlier-adjusted causal
estimates for relationships where both the global and
distortion tests provide evidence of horizontal pleiotropy
(with both P values < 0.05).
To further examine the role of adult BMI on the ob-
served relationships with age at menarche, we also con-
ducted multivariable Mendelian randomization in UK
Biobank, which is conceptually equivalent to using trad-
itional multivariable regression techniques to identify
the independent associations between multiple expo-
sures and an outcome of interest (see Additional file 1)
to estimate effects of age at menarche independent of
adult BMI (i.e., the effect of age at menarche on the
health-related traits not via BMI). We also adjusted for
height using multivariable Mendelian randomization
(the genetic risk score for height included 3285 variants
identified in the most recent GWAS) in the analyses of
lung function [30].
While one-sample and two-sample Mendelian
randomization have the same three key assumptions,
two-sample Mendelian randomization approaches vary
in the extend and ways that the second assumption can
be violated, which means that comparing results from
both approaches is useful. In one-sample Mendelian
randomization, causal estimates are robust to misspecifi-
cation of the SNP-exposure association model (i.e., pres-
ence of interactions or nonlinear effects) [41]. In
comparison, in two-sample Mendelian randomization,
there is a risk of bias if the exposure/outcome relation-
ship varies between the two samples used to obtain the
necessary effect estimates. Furthermore, in one-sample
Mendelian randomization, compared with two-sample
MR, it is possible to avoid bias resulting from having to
use summary data (in two-sample MR) that has been
conditioned on other variables that can result in collider
bias [42]. An important strength of the two-sample
Mendelian randomization approach is the number of
sensitivity analyses developed to explore potential
presence of bias due to horizontal pleiotropy [41]. In the
presence of weak instrument bias, estimates from one-
sample Mendelian randomization will be biased towards
the multivariable regression (observational) estimate and
in the presence of residual confounding may be biased
(commonly away from the null) [41]. By contrast, the
estimate from the two-sample Mendelian randomization
will be biased towards the null [41]. The statistical
analyses were conducted using Stata version 15
(StataCorp, Texas) and R version 3.5.1 (R Foundation,
www.R-project.org). The analysis code is provided in
Additional file 2.
Results
The mean age at menarche in UK Biobank was 12.9
years (standard deviation 1.6 years). The main GRS
(GRS-all), including 360 SNPs, explained 6.1% of the
variation in age at menarche (F-statistic = 1043) (Add-
itional file 3: Table S1). Steiger filtering found that 27 of
the 360 SNPs included in the GRS for age at menarche
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explained more of the variation in adult BMI than
age at menarche. The genetic risk score including 333
SNPs after Steiger filtering (GRS-Steiger) explained
5.8% of the variation in age at menarche (F-statistic =
979). After excluding SNPs associated with childhood
BMI, the GRS including the remaining 353 SNPs
(GRS-child BMI) explained 6.0% of the variance in age
at menarche (F-statistic = 1012), and after excluding
childhood and/or adult BMI associated SNPs, the
GRS including the remaining 154 SNPs (GRS-BMI) ex-
plained 3.0% of the variance (F-statistic = 489). The
main GRS (GRS-all) was not associated with study
center or genotyping chip after adjusting for the first
10 genetic principal components (P value 0.2 for chip
and ≥ 0.6 for study center). There was no strong evi-
dence of a relationship between the GRS-all and age
at recruitment (P value 0.4). The linear correlation
coefficient was − 0.002.
Of the 17,893 tests performed, our MR-pheWAS ana-
lysis (using GRS-all) identified potential effects of age at
menarche on 619 traits (3.5% of all traits) at a false dis-
covery rate of 5% (P value ≤ 1.73 × 10−3), and 295 (1.6% of
all traits) potential effects when using the more stringent
Bonferroni-corrected threshold (P value ≤ 2.79 × 10−6). A
quantile-quantile plot of P values is shown in Fig. 3a. The
distribution of findings across categories of traits is shown
in Fig. 4a, while a detailed list describing the findings and
the direction of the effects is provided in Additional file 3:
Table S2. Of the 619 potential effects of age at menarche,
88 were on BMI and other anthropometric traits, 111
were potential effects on diet, and 29 captured measures
of physical activity. We also noted potential effects of
younger age at menarche on lower lung function, greater
heel BMD, increased risk of psychosocial/mental health is-
sues, poorer cognition, increased report of physical health
problems, and measures of reproductive health.
Fig. 3 QQ-plots for the Mendelian randomization analysis of age at menarche in relation to 17,893 traits. a Main analysis (GRS-all). b Sensitivity
analysis excluding SNPs that explained more of the variation in BMI than age at menarche (GRS-Steiger). c Sensitivity analysis excluding SNPs
associated with childhood BMI (GRS-child BMI). d Sensitivity analysis excluding SNPs associated with childhood and/or adult BMI (GRS-any BMI). Green
dashed line: Bonferroni-corrected threshold (P value≤ 2.79 × 10−6). Blue dashed line: false discovery rate threshold (P value≤ 1.73 × 10−3 for
analysis using GRS-all; P value≤ 1.61 × 10
−3 for the analysis using GRS-Steiger; P value≤ 1.68 × 10
−3 for analysis using GRS-child BMI; P value≤ 1.03 ×
10−4 for analysis using GRS-any BMI). Black dotted line: actual = expected. Black points: results of tests performed in MR-pheWAS. Red stars: results
with P values < 2.23 × 10−308
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For the reproductive health indicators, we observed
potential effects of younger age at menarche on younger
age at first birth, younger age at last birth, earlier use of
exogenous hormones (both oral contraceptives and
hormone replacement therapy), lower risk of bilateral
oophorectomy, higher likelihood of pregnancy termina-
tions, lower risk of miscarriage, and higher likelihood of
having already experienced menopause. Regarding spe-
cific health outcomes, we identified potential effects of
younger age at menarche on greater risk of
Fig. 4 Manhattan plot of results for Mendelian randomization analysis of age at menarche in relation to 17,893 traits. a Main analysis
(GRS-all). b Sensitivity analysis excluding SNPs that explained more of the variation in BMI than age at menarche (GRS-Steiger). c Sensitivity
analysis excluding SNPs associated with childhood BMI (GRS-child BMI). d Sensitivity analysis excluding SNPs associated with childhood and/
or adult BMI (GRS-any BMI). Gray line: Bonferroni-corrected threshold (P value ≤ 2.79 × 10
−6). Blue line: false discovery rate threshold (P
value ≤ 1.73 × 10−3 for analysis using GRS-all; P value ≤ 1.61 × 10
−3 for the analysis using GRS-Steiger; P value ≤ 1.68 × 10
−3 for analysis using
GRS-child BMI; P value ≤ 1.03 × 10
−4 for analysis using GRS-any BMI). All findings above the red line indicate results that have P values smaller
than the limit for what is quantified in R software (P value < 2.23 × 10−308)
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cardiometabolic outcomes (type 2 diabetes, hyperten-
sion, ischemic heart disease, cerebral infarction, and an-
gina). Other potential effects of younger age at
menarche included increased risk of self-reported osteo-
porosis, arthrosis, osteoarthritis, and cholecystitis.
More novel findings included potential effects of
younger age at menarche on increased risk of neuroti-
cism, sleep disorders/chronotype, and having been
sexually abused during childhood. Results of our sen-
sitivity MR-pheWAS analysis adjusting for genotyping
chip were similar to the main analysis, with 617 find-
ings below a 5% false discovery rate P value threshold
and 295 below a Bonferroni-corrected P value thresh-
old, with similar traits identified in these and the
main analysis (Additional file 3: Table S3).
The sensitivity analysis using Steiger filtering to exclude
SNPs that explained more of the variation in BMI from
the genetic risk score yielded a slightly smaller number of
findings, with 576 at the 5% false discovery rate threshold,
out of which 245 were below the Bonferroni-corrected P
value threshold (Figs. 3b, 4b, Additional file 3: Table S4).
A total of 207 of the 245 findings that were below the
Bonferroni-corrected P value threshold after Steiger filter-
ing also passed this threshold in the main analysis.
Overall, the results were also similar when we ex-
cluded SNPs associated with childhood BMI from the
GRS for age at menarche (GRS-child BMI), yielding 601
significant findings below the 5% false discovery rate
(P value ≤ 1.68 × 10−3), out of which 290 were below
the Bonferroni-corrected threshold, and the outcomes
showing potential effects consistent with those in the
main analysis (Figs. 3c, 4c, and Additional file 3:
Table S5).
When we excluded all SNPs associated with childhood
or adult BMI from the GRS for age at menarche
(GRS-BMI), we identified 37 potential effects of age at
menarche below false discovery rate (P value ≤ 1.03 ×
10−4), out of which 29 were below the Bonferroni-
corrected threshold (Figs. 3d, 4d, and Additional file 3:
Table S6). These 37 identified relationships were a sub-
set of those identified in our main analyses (GRS-all).
Despite the exclusion of all SNPs associated (at a
genome-wide significant level) with BMI, we still ob-
served a potential effect of younger age at menarche on
higher adult BMI (at a mean age of 57), lower height,
lower lung function, greater BMD, and higher risk of
hypertension. We also found a potential effect of youn-
ger age at menarche on younger age at first sexual inter-
course, younger age of starting to use oral
contraceptives, and younger age at first delivery among
others.
We attempted to replicate some of our findings in inde-
pendent samples. For ease of comparability, we show the
effect estimates from an instrumental variable analysis in
UK Biobank using the same standardization/adjustment
strategy applied in the published GWAS studies (see Add-
itional file 1 for details). We also show the results for UK
Biobank only adjusting for age and the first 10 genetic
principal components, for BMD and lung function (Add-
itional file 4: Figure S1 and S2, respectively). For heel
BMD, we found little evidence of a difference between the
estimates in UK Biobank and GEFOS, although the confi-
dence intervals in GEFOS were wide and included the null
value (Fig. 5; I2 heterogeneity statistic P values ≥ 0.08). We
observed little evidence for an increase in both femoral
neck and lumbar spine BMD per year decrease in age at
menarche in GEFOS as all confidence intervals in-
cluded the null (Fig. 5). The intercept from the MR-
Egger regression was consistent with the null (no dir-
ectional horizontal pleiotropy) for all BMD replication
analyses except the main analysis (GRSall) of heel
BMD in GEFOS (Additional file 3: Table S7; MR-
Egger intercept P value = 0.01).
For FEV1 and FVC, the potential effects of age at
menarche in UK Biobank and the replication cohorts
(SpiroMeta and CHARGE) were consistent, although
the majority of confidence intervals in replication ana-
lyses included the null value (Figs. 6 and 7; all I2 het-
erogeneity statistic P values ≥ 0.07). We observed no
strong evidence of an effect of age at menarche on
the FEV1/FVC ratio (Figs. 6 and 7). The intercepts
from the MR-Egger regression for the lung function
measures were consistent with the null (Add-
itional file 3: Table S7; P values > 0.2), except for
FEV1/FVC in SPIROMETA (P value = 0.04). There
was no strong evidence to support an effect of age at
menarche on neuroticism in the GPC consortium
(Fig. 8), although estimates were largely consistent
with those in UK Biobank (all I2 heterogeneity statis-
tic P values ≥ 0.14 except for weighted median
approach for which I2 P value = 0.02). The MR-Egger
intercept for the regression of age at menarche on
neuroticism in the GPC consortium also indicated
evidence of unbalanced directional pleiotropy (Add-
itional file 3: Table S7; P value 0.02). In the Avon
Longitudinal Study of Parents and Children, the GRS
for age at menarche explained 7.6% of the variation
in age at menarche (Additional file 3: Table S8). The
results from our replication analysis of childhood sex-
ual abuse were consistent with the results in UK Bio-
bank (I2 heterogeneity statistic P value = 0.9), although
the confidence interval was very wide and included
the null value (Fig. 9). The MR-PRESSO results from
the global test for horizontal pleiotropy and the dis-
tortion test for all of the relationships evaluated in
the follow-up analyses (presented in Additional file 3:
Table S9) found little evidence of horizontal plei-
otropy, as none of the effect estimates examined
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showed both global and distortion tests with P values
< 0.05. We therefore do not present the causal effect
estimates after adjustment for outliers.
The genetic risk scores for adult BMI and height ex-
plained 6% and 27% of the variation in these traits in UK
Biobank, respectively (Additional file 3: Table S10).
Using multivariable Mendelian randomization, we found
evidence of an independent effect of earlier menarche
on heel BMD, FEV1, FVC, and neuroticism after ac-
counting for adult BMI, but little evidence of an inde-
pendent effect on risk of childhood sexual abuse and
obstructive lung disease (Additional file 3: Table S11).
Fig. 5 Estimates of the potential causal effect of age at menarche on bone-mineral density. BMD, bone-mineral density; BMI, body mass index; CI,
confidence interval; UKBB, UK Biobank. The results reflect standard deviation difference in BMD measurements per year decrease in age at
menarche. The BMD measurements were standardized by age, weight, height (heel BMD only), and genomic principal components. The
measurement of femoral neck BMD was available for 22,990 women of European ancestry from the GEFOS consortium, lumbar spine BMD was
available for 22,177 women of European ancestry from the GEFOS consortium, and heel BMD was available for 4566 individuals of European
ancestry. For the GEFOS consortium, the main analysis of femoral and lumbar spine BMD included 263 autosomal SNPs in the genetic risk score
for age at menarche, while the main analysis of heel BMD included 252 SNPs. The sensitivity analysis of femoral and lumbar spine BMD excluding
BMI-related SNPs included 166 SNPs in the genetic risk score for age at menarche, while the sensitivity analysis of heel BMD included 158 SNPs
Fig. 6 Estimates of the potential causal effect of age at menarche on adult standardized lung function measurements. BMI, body mass index; CI,
confidence interval; FEV1, forced expiratory volume at 1 s; FVC, forced vital capacity; UKBB, UK Biobank. The results display the change in the
ranked-based inverse normal transformed spirometry measurements per year decrease in age at menarche. The spirometry measurements were
standardized by age, height, smoking status, and genomic principal components. The analysis in SpiroMeta included 79,055 individuals of
European ethnicity. For the SpiroMeta consortium, the main analysis included 328 autosomal SNPs in the genetic risk score for age at menarche,
while the sensitivity analysis excluding all SNPs related to childhood and/or adult BMI included 200 autosomal SNPs
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There was little evidence to support a relationship be-
tween age at menarche and lung function independently
of height (Additional file 3: Table S11), with effect esti-
mates attenuating towards the null.
Discussion
We found that younger age at menarche has a potential
effect on a broad range of health-related traits. When we
accounted for the genetic overlap between age at menar-
che and BMI, the number of potential effects identified
in our MR-pheWAS at a 5% false discovery rate dropped
from 619 to 37, though whether removing all BMI-
related SNPs reduced bias is unclear as this could be re-
moving a potential causal path between age at menarche
and the outcome that is mediated by adult BMI. In rela-
tion to this, the majority of the potential causal effects
(576/619) remained when we removed the genetic vari-
ants that explained more of the variation in BMI than
age at menarche (the variants most likely to reflect hori-
zontal pleiotropic pathways).
We conducted replication and follow-up analyses to
test Mendelian randomization assumptions following
our MR-pheWAS for four of the potential effects identi-
fied. While the estimated effects of younger age at me-
narche on lower lung function and higher BMD were
consistent in UK Biobank and the replication cohorts,
our replication analyses were undertaken in smaller sam-
ples than UK Biobank and had limited statistical power
particularly for the binary childhood sexual abuse. This
meant that with the exception of an effect of younger
age at menarche with higher BMD, the confidence inter-
vals for the replication estimates included the null. Add-
itional replication studies of these findings are therefore
necessary when larger study populations (or published
GWAS studies) of these outcomes become available. Fu-
ture studies should also follow-up other potential effects
identified in our MR-pheWAS which we did not follow-
up to estimate the magnitude of the causal effects and
investigate validity of Mendelian randomization
assumptions.
In common with most existing Mendelian
randomization studies, including previous studies of the
effects of age at menarche on hypothesized outcomes [9,
11, 12, 14–20], we did not explore potential nonlinear
effects of age at menarche on outcomes. The reason we
have not done this and it is rarely done in other studies
is because current methods are only feasible in one-
sample MR and require very large sample sizes, and the
choice of where to put thresholds (for examining MR ef-
fects in subsets across the distribution) is unclear [43].
As methods are further developed, including for poten-
tial use in two-sample MR, this could be further ex-
plored in future studies that follow up specific findings
from our MR-PheWAS.
Due to the number of potential effects on health-
related traits by age at menarche identified in the MR-
PheWAS, we could not follow-up all the findings with
sensitivity and replication analyses. Several other health-
related traits were related to the genetic risk score for
age at menarche in our MR-pheWAS, and their causal
Fig. 7 Estimates of the potential causal effect of age at menarche on adult raw lung function measurements. BMI, body mass index; CI,
confidence interval; FEV1, forced expiratory volume at 1 s; FVC, forced vital capacity; UKBB, UK Biobank. The results display the change in milliliters
in the spirometry measurements (FEV1 and FVC), or change in the proportion airway obstruction (FEV1/FVC), per year decrease in age at
menarche. The estimates are adjusted for age, height, smoking status, and genomic principal components. The analysis of the CHARGE
consortium included 60,552 individuals of European ethnicity. For the CHARGE consortium, the main analysis included 350 autosomal SNPs in the
genetic risk score for age at menarche, while the sensitivity analysis excluding all SNPs related to childhood and/or adult BMI included 213
autosomal SNPs
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relationship with age at menarche should be further ex-
plored in future studies. An underlying genetic predis-
position to younger age at menarche was for example
linked to a younger age at first birth, higher number of
offspring, higher risk of miscarriages/stillbirths, and
higher risk of sleeplessness/insomnia, depression, osteo-
arthritis, arthrosis, and cholecystitis among others. Our
MR-PheWAS included some early-life health-related
outcomes that predate menarche (maternal smoking
around the time of delivery, comparative body size at
age 10, and whether the woman was breastfed). We note
that the MR-PheWAS estimates the association of a gen-
etic predisposition to younger age at menarche with
these outcomes, and this does not necessarily reflect an
effect of age at menarche on these outcomes since there
may have been violations in the instrumental variable as-
sumptions. We chose to follow-up childhood sexual
abuse, but we were not able to distinguish whether the
abuse occurred before or after menarche, as detailed in-
formation on the particular ages during which the abuse
occurred was not available. Considered in the context of
a genetic predisposition to earlier maturation (age at me-
narche occurs at a specific time but pubertal changes
will have started earlier), the potential effect we see here
may also reflect a tendency for girls who undergo pu-
berty earlier to be more prone to abuse.
One limitation of our analysis is the low response in
UK Biobank (5%), which could have resulted in selection
Fig. 8 Estimates of the potential causal effect of age at menarche on neuroticism. BMI, body mass index; CI, confidence interval; GPC, Genetics of
Personality Consortium; UKBB, UK Biobank. The estimates reflect the change in the harmonized neuroticism score per year decrease in age at
menarche adjusted for age and principal components. The Genetics of Personality Consortium (GPC) analysis included 63,661 individuals. For the
GPC consortium, the main analysis included 344 SNPs in the genetic risk score for age at menarche, while the sensitivity analysis excluding SNPs
associated with BMI included 208 SNPs
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bias [44, 45]. Participants in UK Biobank have been
shown to be healthier and of a higher socioeconomic
position compared to other estimates for the British
population [46]. This could have resulted in a lower bur-
den of some of the health-related outcomes evaluated,
such as a lower proportion of smokers, lower mean
BMI, lower overall CVD risk (less diabetes and less
hypertension), and less psychological problems, among
others. The effect of potential selection bias likely varies
across the large number of health-related outcomes eval-
uated. Reassuringly, the mean age at menarche was as
expected based on the estimated age at menarche in the
general population [47]. Recruitment into the cohort is
also restricted to individuals who had survived until the
age at which time they were recruited, meaning that if
age at menarche is causally related to (premature) mor-
tality, survival bias may have influenced our findings, as
it would have in any previous prospective studies.
A second limitation is the statistical power of our rep-
lication analyses. We conducted post hoc power calcula-
tions to evaluate the power of our replication analyses.
Assuming a type 1 error rate of 5%, and that the instru-
ment explains 5% of the variation in age at menarche,
we calculated the minimal effect detectable with 80%
power (Supplement Table S12). The effect estimates re-
flect the change in the standard deviation of the continu-
ous outcomes per standard deviation decrease in age at
menarche. These results indicated that we were ad-
equately powered (80%) to detect a standard deviation in
the continuous outcomes ranging from 0.04 for the lung
function measures in the CHARGE consortium to 0.17
for heel bone-mineral density in the GEFOS consortium.
We were further powered to detect a twofold increase in
the odds of sexual abuse per standard deviation increase
in age at menarche in Avon Longitudinal Study of
Parents and Children. The replication analyses were
Fig. 9 Estimates of the potential causal effect of age at menarche on risk of sexual abuse. ALSPAC, Avon Longitudinal Study of Parents and
Children; BMI, body mass index; CI, confidence interval; UKBB, UK Biobank. The ordinal response scale to sexual abuse in UK Biobank was
converted to a binary variable denoting whether the participant reported any history of childhood sexual abuse, to be comparable to the
replication cohort. The estimates reflect the change in risk of sexual abuse per year decrease in age at menarche after adjusting for 5 principal
components. The analysis of the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort included 5953 women. For ALSPAC, the main
analysis included 342 SNPs in the genetic risk score for age at menarche, while the sensitivity analysis excluding SNPs associated with BMI
included 208 SNPs
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therefore powered to detect modest effect estimates
similar to that observed in UK Biobank, with the excep-
tion of the analysis in Avon Longitudinal Study of
Parents and Children. Thus, for this outcome in particu-
lar, further replication in larger studies is necessary. To
our knowledge, we have used the largest sample sizes
currently available for replication (i.e., the largest sam-
ples with the relevant outcome and genetic data).
A strength of our study is the use of genetic variants
as instrumental variables to reduce the risk of confound-
ing. However, the weights we used to generate our GRS
included a subpopulation of women participating in UK
Biobank. This overfitting of the estimated coefficients
for the relationship between the SNPs and age at
menarche to UK Biobank could therefore have contrib-
uted to an overestimation of the amount of variation in
age at menarche explained by the GRS. On the other
hand, the known “winner’s curse” in GWAS studies
might also lead to an underestimation of causal effect
estimates using Mendelian randomization [48]. We
attempted to minimize the risk of bias due to population
stratification by restricting to individuals of European
ethnicity and adjusting for genetic principal components.
However, this limits the generalizability of our results to
people from other backgrounds. A core Mendelian
randomization assumption states that the genetic instru-
ments should only affect the outcome through pathways
that are via the exposure of interest (which may be vio-
lated by horizontal pleiotropy). The GRS for age at me-
narche includes a large number of genetic variants. This
increases the likelihood that horizontal pleiotropy may
be biasing our results. However, we estimated causal
effects on our follow-up analyses using two-sample
Mendelian randomization methods that require different
assumptions about the extent that the exclusion restric-
tion can be violated (e.g., the extent that horizontal plei-
otropy can occur) and tested for unbalanced horizontal
pleiotropy using MR-Egger regression and found little
evidence of this for these outcomes. The self-reported
information used to create a score for neuroticism and
to define a history of childhood sexual abuse did not
directly compare across UK Biobank and the replication
cohorts. However, the point estimates particularly for
sexual abuse were remarkably similar.
Due to the genetic correlation between age at menar-
che and BMI, we repeated the analyses excluding SNPs
associated with BMI at a Bonferroni-corrected level from
the age at menarche GRS. Notably, the GRS-BMI for age
at menarche excluding SNPs associated with childhood
and adult BMI was still associated with adult BMI (the
PHESANT estimated change in the inverse ranked
transformed BMI per allele increase was 0.006 (95% CI,
0.005, 0.006) for GRS-all, while it was 0.002 (95% CI,
0.002, 0.003) for GRS-BMI). This is likely due to the
presence of SNPs with modest effects on BMI that did
not reach the Bonferroni-corrected P value threshold in
the published GWAS of childhood and adult BMI.
Steiger filtering indicated that only 27 of the 360 SNPs
included in the GRS for age at menarche explained more
of the variation in BMI than age at menarche. The low
proportion of the GRS SNPs that explained a greater
proportion of variation in BMI than age at menarche
suggests that most of the SNPs are valid instruments for
age at menarche and their relationship with BMI is
downstream of age at menarche (reflecting that BMI is a
potential mediator of the effects of interest). This is why
we present the findings from the genetic risk score in-
cluding all genetic variants as the main analysis. We
conducted multivariable Mendelian randomization in
UK Biobank, which also suggested effects of age at me-
narche on heel BMD, FEV1, FVC, neuroticism, and
childhood sexual abuse independent of BMI. In our rep-
lication analysis of lung function and neuroticism, we
had to use estimates of the effect of the SNPs on the
outcomes including both sexes, as GWAS results of
these traits by sex were not available. However, there is
evidence that a large proportion of the SNPs included in
the GRS for age at menarche also predict puberty devel-
opment in a similar way in males (i.e., those predicting
early pubertal development in females also reflect an
earlier puberty development in males) [16]. We did not
conduct multivariable Mendelian randomization for the
entire MR-PheWAS, as MR-pheWAS is hypothesis-
generating, identifying potential effects which subse-
quently need to be followed up with further analyses.
Multivariable mendelian randomization also has some
limitations, as it requires the variables used in the model
to have similar instrument strength [49]. The stronger
instrument strength for BMI compared with age at me-
narche could therefore have attenuated our findings and
caused us to miss potential causal effects of age at
menarche. PHESANT performs the test of the associ-
ation of a genetic instrumental variable with a wide
range of outcomes (here ~ 18,000 outcomes) to iden-
tify outcomes for which there is evidence of a poten-
tial causal effect, providing the opportunity to identify
novel causal effects. It was not possible for us to
complete replication and assumption testing for all of
the potential effects identified (over 600 at a 5% false
discovery rate), and we therefore followed up 4 se-
lected examples identified in our MR-pheWAS to es-
timate the magnitude of the causal effect and explore
validity of instrumental variable assumptions. Thus, a
useful further advance may be automation of follow-
up analyses and replications, for example, using a sys-
tem like MR-Base. The lack of available data to
undertake replication and assumption testing for all
outcomes will remain an issue, but with increasing
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amounts of GWAS studies, this will improve over
time.
We found some evidence of an effect of younger age
at menarche on lower lung function in UK Biobank, but
while the confidence intervals were consistent in both
the SpiroMeta and CHARGE consortia replication sam-
ples, the majority of confidence intervals included the
null. Previously, a Mendelian randomization analysis of
age at menarche and lung function using data from the
earlier release of the genetic data from UK Biobank,
where UK Biobank was 1 of 3 cohorts used to estimate
the effect on adult lung function (total n = 46,944
women), also reported lower adult FEV1 and FVC with
younger age at menarche [18]. One potential explanation
for this finding is that younger age at menarche/earlier
exposure to female sex hormones terminates lung
growth at a younger age, and subsequently leads to a
lower maximally attained lung function and lower lung
function in adulthood [50]. This potential explanatory
mechanism was further supported by the fact that we
observed little evidence to support a relationship
between age at menarche and lung function after ac-
counting for adult height in multivariable Mendelian
randomization.
Our results in UK Biobank suggest that younger age at
menarche may result in greater adult heel BMD, but
while our replication estimates were largely consistent
with our UK Biobank results, confidence intervals were
wide and included the null. A beneficial effect of age at
menarche on BMD, if one exists, would be consistent
with results of a recent Mendelian randomization study
indicating that a delayed onset of puberty may causally
affect fracture risk [20]. The importance of female sex
hormones for bone health is established and is clearly
reflected in the reduction of bone mass and increased
risk of osteoporosis among postmenopausal women [51].
Our results in UK Biobank also suggested that younger
age at menarche might result in higher levels of neuroti-
cism. Notably, a previously published BMI MR-pheWAS
supported a causal effect of BMI on neuroticism [22].
Any potential explanatory mechanisms for a relationship
between age at menarche and neuroticism are less evi-
dent than for lung function and BMD and need to be
further investigated. We also observed evidence of a
higher risk of sexual abuse among women with a youn-
ger age at menarche, although the replication analysis
was underpowered. This association has been previously
reported [52–54].
The main contribution of our study is to increase un-
derstanding of potential effects of age at menarche on
health-related traits. While it is not possible to directly
intervene on age at menarche, it is important to under-
stand the causal pathways to disease and the role that
pubertal timing might play. Our study therefore lays the
foundations for future research into the biosocial mecha-
nisms that might explain how age at menarche might in-
fluence the health-related traits, some of which are likely
to be modifiable. As several of the health-related traits
are common and complex with multiple risk factors, if
our findings are further replicated in larger cohorts pro-
viding more precise estimates, they can be used to give
advice on risk. For example, if it is established that youn-
ger age at menarche is causally related to lower lung
function, girls with younger age at menarche might be
advised to remain physically fit to maintain their lung
function. Furthermore, knowing that you have one
(unmodifiable) risk factor for some health outcomes is
useful for women, as it means they should attempt to
avoid any additional adverse modifiable risk factors.
Conclusions
Our results suggest that younger age at menarche has
potential effects on a broad range of health-related traits.
Follow-up analysis indicated imprecise evidence of an ef-
fect of younger age at menarche on higher bone-mineral
density, lower lung function, greater score for neuroti-
cism, and greater risk of childhood sexual abuse in the
smaller replications samples available, and these rela-
tionships should therefore be re-examined when larger
study populations become available. Future studies are
needed to further investigate the potential effects which
we did not follow-up here. Additional studies using
other designs with different biases and sufficient statis-
tical power to replicate our findings would also be use-
ful. Where future studies provide strong evidence for
causal effects of age at menarche on several outcomes,
studies to explore potential modifiable mechanisms to
mitigate any effect of age at menarche will be important.
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